REAL-WORLD DATA ON THE COMPARISON OF LDL-C LOWERING EFFECTS BETWEEN ALIROCUMAB AND EVOLOCUMAB

被引：0
|
作者：
Lin, D. -Y. [1 ]
Tsai, C. -L. [1 ]
Chuang, J. -Y. [2 ]
Liang, C. -H. [2 ]
Chen, Y. -H. [3 ]
Chang, Y. -H. [4 ]
Yeh, H. -I. [1 ]
Lin, C. -F. [5 ,6 ]
机构：
[1] MacKay Mem Hosp, Dept Cardiol, Taipei, Taiwan
[2] MacKay Mem Hosp, Dept Med Educ, Taipei, Taiwan
[3] Taipei Med Univ, Coll Publ Hlth, Sch Publ Hlth, Taipei, Taiwan
[4] MacKay Mem Hosp, Dept Pharm, Taipei, Taiwan
[5] MacKay Mem Hosp, Dept Cardiol, Taipei, Taiwan
[6] MacKay Med Coll, Dept Med, New Taipei, Taiwan
来源：
ATHEROSCLEROSIS | 2022年 / 355卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EP628
引用
收藏
页码：E300 / E300
页数：1
相关论文
共 50 条
  • [1] Real-World Data on Comparison of Lipid-Lowering Effects between Alirocumab and Evolocumab in Patients with Hypercholesterolemia
    Lin, Dai-Yi
    Tsai, Chia-Ling
    Chang, Ya-Hui
    Liang, Chih-Hung
    Chuang, Jen-Yu
    Chen, Yi-Han
    Yeh, Hung-, I
    Lin, Chao-Feng
    ACTA CARDIOLOGICA SINICA, 2022, 38 (06) : 778 - 783
  • [2] Lowering LDL-C with alirocumab, an investigational PCSK9 inhibitor
    Edelberg, Jay
    CLINICAL LIPIDOLOGY, 2014, 9 (06) : 603 - 606
  • [3] PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
    Juan Ceballos-Macias, Jose
    Lara-Sanchez, Carolina
    Flores-Real, Jorge
    Alberto Aguilar-Salinas, Carlos
    Ortega-Gutierrez, Guillermo
    Vargas-Sanchez, Joel
    Madriz-Prado, Ramon
    Derosa, Giuseppe
    Rodriguez-Benitez, Hazel
    Baltazar-Romero, Ricardo
    Jose Lopez-Mezquita, Dante
    JOURNAL OF THE ENDOCRINE SOCIETY, 2021, 5 (01) : 1 - 6
  • [4] Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice
    Gandhi, Sanjay K.
    Jarbrink, Krister
    Fox, Kathleen M.
    Brandrup-Wognsen, Gunnar
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (12) : 2817 - 2828
  • [5] Peripheral arterial Disease LDL-C and cardiovascular Risk significantly lowering with Evolocumab
    Unger-Hunt, Lydia
    AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2018, 11 (02): : 68 - 70
  • [6] IMPACT OF ANTI-DRUG ANTIBODIES TO ALIROCUMAB ON LDL-C LOWERING EFFICACY AND SAFETY
    Roth, Eli M.
    Goldberg, Anne
    Catapano, Alberico
    Torri, Albert
    Brunet, Aurelie
    Lecorps, Guillaume
    Colhoun, Helen
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 1863 - 1863
  • [7] Impact of Lowering LDL-C With Evolocumab on Everyday Cognition in Participants From the FOURIER Trial
    Gencer, Baris
    Mach, Francois
    Guo, Jianping
    Im, Kyungah
    Ruzza, Andrea
    Wang, Huei
    Kurtz, Christopher
    Pedersen, Terje R.
    Keech, Anthony C.
    Ott, Brian
    Sabatine, Marc S.
    Giugliano, Robert P.
    CIRCULATION, 2019, 140
  • [8] Long-Term Neurocognitive Safety of LDL-C Lowering With Evolocumab: OpenLabel Extension Data From FOURIER
    Zimerman, Andre
    O'Donoghue, Michelle
    Ran, Xinhui
    Im, KyungAh
    Ott, Brian F.
    Mach, Francois
    Zavitz, Kenton
    Kurtz, Christopher E.
    Monsalvo, Maria L.
    Wang, Bei
    Atar, Dan
    Keech, Anthony
    Sabatine, Marc S.
    Giugliano, Robert
    CIRCULATION, 2023, 148
  • [9] Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial
    Roth, Eli M.
    Kastelein, John Jp
    Cannon, Christopher P.
    Farnier, Michel
    McKenney, James M.
    DiCioccio, A. Thomas
    Brunet, Aurelie
    Manvelian, Garen
    Sasiela, William J.
    Baccara-Dinet, Marie T.
    Zhao, Jian
    Robinson, Jennifer G.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (05) : 707 - 719
  • [10] Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US
    Marrett, Elizabeth
    Zhao, Changgeng
    Zhang, Ning Jackie
    Zhang, Qiaoyi
    Ramey, Dena R.
    Tomassini, Joanne E.
    Tershakovec, Andrew M.
    Neff, David R.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2014, 10 : 237 - 246
12345